Biotech and Pharmaceuticals Biotechnology

More

  • Beigene, Editas Medicine shares rise in market debuts Wednesday, 3 Feb 2016 | 1:36 PM ET

    WASHINGTON— Shares of medical sector companies Beigene Ltd. of China and Editas Medicine Inc. of Massachusetts climbed Wednesday in their market debuts. Beigene shares rose $4.58, or 19.1 percent, to $28.10 in midday trading. Genomic technology company Editas Medicine, based in Cambridge, Massachusetts, also made its market debut on the Nasdaq.

  • Bill MIller's 'genius' play on synthetic biology Wednesday, 3 Feb 2016 | 7:32 AM ET
    Bill MIller's 'genius' play on synthetic biology

    Bill Miller, LMM chairman & CIO, weighs in on why he likes auto stocks and biotech company Intrexon.

  • This transaction is about growth: Syngenta chairman Wednesday, 3 Feb 2016 | 2:26 AM ET
    This transaction is about growth: Syngenta chairman

    Michel Demaré, chairman of Syngenta, says the takeover deal with state-owned ChemChina is good value for shareholders.

  • Pacific Biosciences shares were trading up 25 percent at $12.70 in afternoon trading in New York on the news, giving the company a market value of close to $1 billion. Based in Menlo Park, California, Pacific Biosciences focuses primarily on developing and manufacturing systems for gene sequencing. In 2013, Roche, which is based in Basel, Switzerland, penned a...

  • Theranos under fire Thursday, 28 Jan 2016 | 11:17 AM ET
    Theranos under fire

    Regulators warn that new Theranos lab in California is unsafe for patients, company says it's taking corrective action. CNBC's Meg Tirrell explains.

  • Pharma, biotech stocks take a hit Thursday, 28 Jan 2016 | 10:53 AM ET
    Pharma, biotech stocks take a hit

    After rash of earnings reports, Abbott Labs, Bristol-Myers Squibb, Celgene and Eli Lilly shares suffer. CNBC's Meg Tirrell reports.

  • *Worsening response rates observed in patients receiving drug. Jan 25- OncoMed Pharmaceuticals Inc lost nearly half its market value after independent investigators informed the company that its pancreatic cancer drug was unlikely to meet the main goal in a mid-stage study. The setback sent the company's shares down by as much 46 percent to a record-low of...

  • Is it time to bet on biotech? Thursday, 14 Jan 2016 | 2:06 PM ET
    Is it time to bet on biotech?

    JMP Securities President Mark Lehmann explains why now is the time to get in on biotech stocks.

  • Pharma needs to rethink pricing: Novartis CEO Monday, 11 Jan 2016 | 11:23 AM ET
    Pharma needs to rethink pricing: Novartis CEO

    Novartis CEO Joe Jimenez says the pharma industry needs to rethink pricing as drug combinations are increasingly being used to treat cancer and other diseases.

  • Celgene replaces CEO, guides lower Monday, 11 Jan 2016 | 11:23 AM ET
    Celgene replaces CEO, guides lower

    Celgene's Mark Hugin is replaced by Mark Alles as CEO, and the company lowers earnings estimates, reports CNBC's Sue Herera.

  • Lilly's Lechleiter: Firms to make drugs more affordable

    Eli Lilly's John Lechleiter says he's optimistic about the year ahead for the pharmaceuticals industry, including measures to help patients afford prescription drugs.

  • The latest on Lilly's Alzheimer's trials Monday, 11 Jan 2016 | 10:14 AM ET
    The latest on Lilly's Alzheimer's trials

    Eli Lilly CEO John Lechleiter discusses clinical trials of his company's treatments for Alzheimer's disease.

  • Activist Bill Ackman trims Pershing Square's Valeant stake

    Activist investor Bill Ackman's Pershing Square Capital Management is cutting its stake in Valeant Pharmaceuticals, reports CNBC's Seema Mody.

  • Cloning giant: 'We won't make Frankensteins'—for now Saturday, 26 Dec 2015 | 9:56 AM ET
    Three cloned puppies snuggle in an incubator at a Boyalife Group facility in Tianjin, China, in 2014.

    A Chinese firm that's building the world's biggest animal cloning factory has vowed not to use the technology on people—for now. NBCNews reports.

  • StemCells Inc says spinal injury therapy shows promise Wednesday, 18 Nov 2015 | 4:05 PM ET

    Nov 18- StemCells Inc said its experimental stem cell therapy improved the functioning and strength of limbs in patients with spinal cord injuries, becoming the second company to report promising data on the treatment for such injuries. StemCells' research centers around the treatment for spinal cord injuries, visual problems that begin at the retina and...

  • GSK CEO: Drug debate 'overly focused' on price Tuesday, 3 Nov 2015 | 3:10 PM ET
    GSK CEO: Drug debate 'overly focused' on price

    GlaxoSmithKline CEO Sir Andrew Witty discusses the drug environment as pressure mounts over higher prices.

  • GSK CEO: Novartis deal is only deal we need Tuesday, 3 Nov 2015 | 3:10 PM ET
    GSK CEO: Novartis deal is only deal we need

    GlaxoSmithKline CEO Sir Andrew Witty weighs in on why his company has no immediate deal plans in the drug space.

  • Valeant probed by US prosecutors on drug pricing Thursday, 15 Oct 2015 | 1:16 AM ET

    U.S. prosecutors are probing Valeant Pharmaceuticals over how it prices and distributes drugs, the Canadian pharma giant revealed late Wednesday.

  • Here's what Chinese consumers will want next Wednesday, 14 Oct 2015 | 10:00 AM ET
    Human brain high tech illustration

    And artificial intelligence will be hot for Chinese consumers, but 3-D printing will be all the rage in Europe.

  • Biotech vs pharma stock: which one should you buy? Friday, 9 Oct 2015 | 2:30 AM ET
    Biotech vs pharma stock: which one should you buy?

    James West, senior healthcare analyst for Results Healthcare, talks about biotech stocks and explains the differences biotech and pharmaceutical companies.